Literature DB >> 29356495

Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.

Mette Ishoey1, Someth Chorn2, Natesh Singh3, Martin G Jaeger2, Matthias Brand2, Joshiawa Paulk1,4, Sophie Bauer2, Michael A Erb1, Katja Parapatics2, André C Müller2, Keiryn L Bennett2, Gerhard F Ecker3, James E Bradner1,4, Georg E Winter2.   

Abstract

Protein degradation is an emerging therapeutic strategy with a unique molecular pharmacology that enables the disruption of all functions associated with a target. This is particularly relevant for proteins depending on molecular scaffolding, such as transcription factors or receptor tyrosine kinases (RTKs). To address tractability of multiple RTKs for chemical degradation by the E3 ligase CUL4-RBX1-DDB1-CRBN (CRL4CRBN), we synthesized a series of phthalimide degraders based on the promiscuous kinase inhibitors sunitinib and PHA665752. While both series failed to induce degradation of their consensus targets, individual molecules displayed pronounced efficacy in leukemia cell lines. Orthogonal target identification supported by molecular docking led us to identify the translation termination factor G1 to S phase transition 1 (GSPT1) as a converging off-target, resulting from inadvertent E3 ligase modulation. This research highlights the importance of monitoring degradation events that are independent of the respective targeting ligand as a unique feature of small-molecule degraders.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29356495     DOI: 10.1021/acschembio.7b00969

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  36 in total

1.  A MedChem toolbox for cereblon-directed PROTACs.

Authors:  Christian Steinebach; Izidor Sosič; Stefanie Lindner; Aleša Bricelj; Franziska Kohl; Yuen Lam Dora Ng; Marius Monschke; Karl G Wagner; Jan Krönke; Michael Gütschow
Journal:  Medchemcomm       Date:  2019-05-28       Impact factor: 3.597

Review 2.  PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.

Authors:  Mariell Pettersson; Craig M Crews
Journal:  Drug Discov Today Technol       Date:  2019-02-13

Review 3.  Proteolysis-targeting chimeras in drug development: A safety perspective.

Authors:  Kevin Moreau; Muireann Coen; Andrew X Zhang; Fiona Pachl; M Paola Castaldi; Goran Dahl; Helen Boyd; Clay Scott; Pete Newham
Journal:  Br J Pharmacol       Date:  2020-02-25       Impact factor: 8.739

4.  Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.

Authors:  George M Burslem; Philipp Ottis; Saul Jaime-Figueroa; Alicia Morgan; Philipp M Cromm; Momar Toure; Craig M Crews
Journal:  ChemMedChem       Date:  2018-07-04       Impact factor: 3.466

5.  Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91.

Authors:  Maha Hanafi; Xinde Chen; Nouri Neamati
Journal:  J Med Chem       Date:  2021-01-28       Impact factor: 7.446

6.  Mechanistic and Structural Features of PROTAC Ternary Complexes.

Authors:  Ryan Casement; Adam Bond; Conner Craigon; Alessio Ciulli
Journal:  Methods Mol Biol       Date:  2021

7.  A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo.

Authors:  Longchuan Bai; Haibin Zhou; Renqi Xu; Yujun Zhao; Krishnapriya Chinnaswamy; Donna McEachern; Jianyong Chen; Chao-Yie Yang; Zhaomin Liu; Mi Wang; Liu Liu; Hui Jiang; Bo Wen; Praveen Kumar; Jennifer L Meagher; Duxin Sun; Jeanne A Stuckey; Shaomeng Wang
Journal:  Cancer Cell       Date:  2019-11-11       Impact factor: 31.743

Review 8.  Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.

Authors:  George M Burslem; Craig M Crews
Journal:  Cell       Date:  2020-01-16       Impact factor: 41.582

9.  A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.

Authors:  Ka Yang; Yu Zhao; Xueqing Nie; Hao Wu; Bo Wang; Chelsi M Almodovar-Rivera; Haibo Xie; Weiping Tang
Journal:  Cell Chem Biol       Date:  2020-05-14       Impact factor: 8.116

Review 10.  Advancing targeted protein degradation for cancer therapy.

Authors:  Brandon Dale; Meng Cheng; Kwang-Su Park; H Ümit Kaniskan; Yue Xiong; Jian Jin
Journal:  Nat Rev Cancer       Date:  2021-06-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.